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Abstract 
Background: Fei-Liu-Ping (FLP) ointment is an oral prescription medication that has been widely applied to treat 
lung cancer patients in China. Regulation of the metastatic microenvironment is an important therapeutic approach 
for prevention and treatment of tumor recurrence and metastasis. The advantage of Traditional Chinese Medicine 
management of lung cancer lies in the prevention of recurrence and metastasis. Our previous study has demon-
strated that FLP ointment could regulate lung inflammatory microenvironment in vitro. However, the effects of FLP 
on the tumor microenvironment in vivo are still poorly understood. The objective of this study is to investigate the 
effect of FLP alone or in combination with celecoxib in the prevention of lung cancer progression by Cyclooxygenase 
(Cox)-2 mediated tumor inflammatory microenvironment in vivo.
Methods: 120 Lewis lung carcinoma xenograft mice were divided equally into four groups: vehicle, FLP, celecoxib, 
and FLP plus celecoxib. The dynamic growth of the xenografted tumors was observed using an in vivo fluorescence 
imaging system. Mice were sacrificed on day 14, day 21, and day 28, and tumor specimens and lung tissues were 
harvested to detect the metastasis-associated protein expression.
Results: Tumor inhibition rate was 15.4, 44.2, 47.4 % at day 14, 37.3, 34.7, 61.5 % at day 21, and 15.5, 10.3, 32.5 % at 
day 28 after treatment of FLP, celecoxib, and FLP plus celecoxib, respectively. Upon treatment of FLP and celecoxib 
together, lung metastasis rate was 30 % (8 metastatic nodules) lower than other groups. FLP inhibited Cox-2 expres-
sion in a time-dependent manner. Moreover, FLP inhibited N-cadherin, matrix metalloproteinases (MMP)-9, and 
Vimentin expression. Treatment of FLP in combination with celecoxib was more effective than FLP or celecoxib alone 
in inhibiting vascular endothelial growth factor, platelet-derived growth factor receptors β, microsomal Prostaglandin 
E synthase-1, MMP-2, MMP-9, N-cadherin, and Vimentin expression, but increased E-cadherin expression.
Conclusions: FLP inhibited tumor growth and metastasis in a Lewis lung xenograft mice model through the Cox-2 
pathway. FLP in combination with celecoxib enhanced the antitumor growth and anti-metastasis effects. Traditional 
Chinese herbs combined with anti-inflammatory drugs might offer a promising strategy to prevent tumor metastasis.
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Background
Lung cancer is the leading cause of cancer-related deaths 
in the world [1]. Despite advances in surgical tech-
niques, chemotherapy, and radiotherapy, the 5-year 
survival rate for lung cancer patients is lower than 20 % 
[2]. The high mortality is likely attributed to early metas-
tasis. Metastatic spread is the critical cause of mortal-
ity and treatment failure [3, 4]. Therefore, development 
of new therapies to treat patients with metastatic lung 
cancer is necessary to reduce mortality rates. Preven-
tion of recurrence and metastasis is an important step 
towards management for lung cancer patients. Research 
on lung cancer has recently focused on tumor microen-
vironment and recognized that alterations in the tumor 
microenvironment are a predictor of tumor occurrence 
and metastasis [5]. Various agents targeting the tumor 
inflammatory microenvironment provide a new thera-
peutic method for preventing tumor metastasis [6]. 
Changes in the tumor microenvironment occur slowly, 
and has certain correlation with maintenance therapy 
to prevent tumor recurrence and metastasis. Currently, 
chemotherapeutic drugs and targeted agents are com-
monly used in maintenance therapy. Pemetrexed and 
Erlotinib are widely used as maintenance therapy for 
advanced non-small cell lung cancer [7, 8]; however, their 
adverse effects and high economic burden reduce patient 
compliance [9].
Tumor microenvironment plays a critical role in tumor 
growth, progression, and metastasis [10]. It is increas-
ingly recognized that tumor inflammatory microenvi-
ronment is closely related to tumor metastasis [11–15]. 
Cyclooxygenase-2 (Cox-2) is a rate-limiting enzyme for 
prostanoid biosynthesis, and plays a crucial role in the 
tumor inflammatory microenvironment [16, 17]. Cox-2 is 
over-expressed in all the metastatic process of cancer and 
involved in angiogenesis, epithelial-mesenchymal transi-
tion (EMT) initiation, and extracellular matrix (ECM) 
destruction [18–21]. Increasing evidence has shown that 
the Cox-2 gene was constitutively over-expressed in most 
human solid tumors, such as colon cancer, breast cancer, 
and lung cancer, and could serve as a predictor of poor 
prognosis [22–24].
Inflammation is necessary to promote cancer initia-
tion and progression through angiogenesis and change 
of tumor microenvironment [25]. Anti-inflammatory 
drugs have become indispensable for cancer prevention 
and treatment. Indeed, long-term use of non steroidal 
anti-inflammatory drugs (NSAIDs), such as aspirin, were 
shown to decrease the risk of colon cancer by 40–50  % 
[26]. Cox-2 inhibitors are amongst the most popular 
medications worldwide. The US Food and Drug Admin-
istration (FDA) approved celecoxib, which is a hallmark 
of COX-2 inhibitors used for tumor prevention, as the 
adjuvant therapy for treatment of familial adenomatous 
polyposis in 1999 [27].
Traditional Chinese Medicine (TCM), as an important 
part of complementary and alternative therapy, exhibit 
advantages in the prevention of tumor recurrence and 
metastasis compared with radiotherapy and chemo-
therapy [28]. TCM is often used for maintenance therapy 
of lung cancer mainly due to its low toxicity or adverse 
effects, less cost, and better improvement in clinical out-
comes [29, 30]. TCM scholars deem that Chinese herbs 
change the tumor microenvironment, such that tumor 
cells become dormant or difficult to survive in the “soil”. 
The adverse effects or costs of Chinese herbs and anti-
inflammatory drugs are far lower than the targeted drugs 
or chemotherapy drugs. However, no previous experi-
mental study has investigated the effect of Chinese herbs 
in combination with anti-inflammatory drugs for pre-
venting tumor metastasis.
FLP ointment inhibits lung cancer invasion by regulat-
ing tumor inflammatory microenvironment through the 
NF-κB signaling pathway [31]. Celecoxib improves tumor 
microenvironment through inhibiting the Cox-2 path-
way. Although FLP ointment has shown to be effective 
in treating lung cancer in vivo, the mechanisms of action 
remain unclear. Whether FLP ointment in combination 
with celecoxib exerts synergistic effects in improvement 
of tumor inflammatory microenvironment or prevents 
progression and metastasis is still poorly understood. The 
objective of the current study is to investigate the effect 
of FLP alone or in combination with celecoxib on tumor 
growth in Lewis lung xenograft model and Cox-2 expres-
sion in lung cancer specimens. Furthermore, we also sought 
to examine the effect of FLP on Cox-2, and other metasta-
sis-related protein expression, in normal lung tissues.
Methods
Drugs and antibodies
FLP ointment (No. Z20063236) was prepared by Phar-
maceutical preparation center of Guang’anmen Hospital, 
China Academy of Chinese Medical Sciences. Celecoxib 
(No. H20120355) was purchased from Pfizer Pharma-
ceuticals LLC (Dalian, China). Antibodies against Cox-
2, E-Cadherin, Vimentin, platelet-derived growth factor 
receptors (PDGFR) β, β-actin, GAPDH, anti-rabbit IgG, 
and horseradish peroxidase (HRP)-linked antibody was 
purchased from Cell Signaling Technology (Cambridge, 
MA, USA). Vascular endothelial growth factor (VEGF), 
N-Cadherin, microsomal Prostaglandin E synthase-1 
(mPGES-1), matrix metalloproteinases (MMP)-2, and 
MMP-9 antibodies were purchased from Abcam (Cam-
bridge, MA, USA). Biotinylated secondary antibod-
ies were purchased from Beijing Xiya Jinqiao Biological 
Technology Co. Ltd.
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Preparation of FLP ointment
The herbs used in FLP ointment are the roots of Astra-
galus membranaceus (Fisch.) Bge.var.mongholicus 
(Bge.) Hsiao (Huang-Qi), Panax quinquefolium L. (Xi-
Yang-Shen), Ophiopogon japonicas (Thunb.) Ker-Gawl. 
(Mai-Dong), Glehnia littoralis Fr. Schmidt ex Miq. (Bei-
Sha-Shen), Agrimonia pilosa Ledeb. (Xian-He-Cao), 
Polygonum bistorta L. (Quan-Shen), Patrinia villosa 
(Thunb.) Juss. (Bai-Jiang-Cao), Panax notoginseng (Burk.) 
F.H. Chen (San-Qi), Fritillaria cirrhosa D.Don (Chuan-
Bei-Mu), Glycyrrhiza uralensis Fisch. (Gan-Cao), Cordy-
crps sinensis(Berk.) Sacc. (Dong-Cong-Xia-Cao), and 
the fruits of Prunus persica (L.) Batsch (Tao-Ren) and 
Prunus armeniaca L. var ansu Maxim. (Xing-Ren). All 
herbs were provided by the Guang’anmen Hospital and 
decocted twice with eightfold volume of distilled water 
for 1  h. The decoction were collected, filtered, merged 
and concentrated to 2 g/mL (equivalent to crude herb 
materials), and stored at 4 °C for oral use.
Animals
Specific pathogen free 6–8-weeks-old male C57BL/6 
mice weighing 20 ± 2 g were purchased from Vital River 
Company (Beijing, China). All the mice were kept under 
a temperature and humidity-controlled animal facility 
with a 12-h light/dark cycle. Mice were had free access 
to feed pellets and tap water. All the experiments were 
carried out in accordance with the guidelines for animal 
experiments of China Academy of Chinese Medical Sci-
ences (IACU numbers: SYXK [Beijing], 2012-0034).
Cell culture
LL/2-luc-M38 cells were kindly provided by the cancer 
institute of Guang’anmen Hospital, Chinese Academy of 
Science. Tumor cells were cultured in Dulbecco’s modi-
fication of Eagle’s medium Dulbecco (DMEM) medium 
containing 10 % fetal bovine serum, 100 U/ml penicillin, 
and 100 mg/ml streptomycin in a cell culture incubator 
at 37 °C under 5 % CO2. Cells were collected at the loga-
rithmic phase of growth by treatment with 0.25 % trypsin 
for 1  min, then the cell concentration was adjusted to 
1 × 106 with phosphate buffer saline (PBS). Trypan Blue 
exclusion test indicated the number of living cells was 
greater than 95 %.
Induction of Lewis lung cancer and intervention
After 3-day acclimation, a subcutaneous injection of 
LL/2-luc-M38 cells 5  ×  105 suspended in 0.2  mL PBS 
was implanted into the right flank of each C57BL/6 
mouse. Starting the next day, forty mice were randomly 
divided equally into four groups: the vehicle control 
group (received the normal saline by gavage), FLP oint-
ment treated group (received 12 g/kg/day FLP by gavage), 
celecoxib treated group (received celecoxib at doses of 
3200 ppm/day in the diet from date of implant until end 
of study [32]), and FLP ointment plus celecoxib group 
(received a combination of celecoxib and FLP treatments 
described above). The mice were treated up to 28  days, 
and some of the mice were sacrificed by cervical decapi-
tation under ether anesthesia at day 14, day 21, and day 
28, and tumor specimens and normal lung tissues were 
harvested and weighed. Part of specimens were exposed 
to 4 % paraformaldehyde fixation for hematoxylin-eosin 
(HE) staining and immunohistochemistry study, and the 
remaining tissues were kept in −80  °C for Western blot 
analysis.
In vivo bioluminescent imaging
In order to observe the dynamic change of inhibitory 
effect of FLP on tumor growth, we compared in  vivo 
tumor imaging with the volume of tumor from the sac-
rificed mice. Imaging was performed at day 7, 14, 21, and 
28 after treatment (N  =  6 for each group). D-luciferin 
(Biotium, Hayward, CA, USA) was dissolved in 15  g/L 
PBS and injected intraperitoneally at a dose of 10  μL/g 
body weight before imaging. Imaging was performed 
40 min later, and then the mice were anesthetized under 
gas-induced anesthesia, and placed in the imaging cham-
ber. Bioluminescent images were acquired by a cryogeni-
cally cooled charge-coupled device camera (IVIS Lumina 
Imaging System, Caliper Life Sciences Inc). A region of 
interest (ROI) was drawn from each tumor location and 
the signal was calculated based on the number of pho-
tons from mouse body surface area (per/s/cm2/sr). Red 
signal represents the high intensity, and purple signal 
represents the low intensity. Finally, the collected data 
were analyzed by statistical analysis.
Tumor inhibition rate
Mice were sacrificed by cervical dislocation at day 14, day 
21, and day 28, and then the tumor tissue were harvested 
and weighed. Tumor inhibition rate was calculated as 
follows: Tumor inhibition rate =  (1 − average weight of 
tumors in treatment group/average weight of tumors in 
control group) × 100 %.
Histological staining and immunohistochemistry
Tumor specimens and normal lung tissues were har-
vested and immersed into 4 % paraformaldehyde fixation 
for 20 h. All the paraffin embedded samples were cut into 
5 μm sections for HE staining, according to standard pro-
tocols. For immunohistochemistry study, each section 
was dehydrated through a graded series of ethanol solu-
tions. Antigen retrieval was performed by incubating the 
specimens with ethylene diamine tetraacetic acid (EDTA) 
in a microwave oven for 150 s. After rinsing with PBS for 
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3 times, these sections were treated with 3  % hydrogen 
peroxide for 10 min to inactivate endogenous peroxides. 
After blocking with 1 % goat serum in PBS for 10 min at 
room temperature, sections were incubated with primary 
anti-Cox-2 (1:200 dilution), anti- mPGES-1 (1:100 dilu-
tion), anti- E-Cadherin (1:300 dilution), anti-N-Cadherin 
(1:300 dilution), anti-Vimentin (1:500 dilution), anti-
VEGF (1:50), anti-PDGFRβ (1:50), anti-MMP-2 (1:50), 
or anti-MMP-9 (1:200) antibodies overnight at 4 °C. Sec-
tions were then incubated with horseradish peroxidase 
(HRP)-conjugated secondary antibody for 20 min at 37 °C 
followed by incubation with diaminobenidine (DAB) for 
3 min. The slides were stained with hematoxylin, differ-
entiated with 1 % hydrochloric acid alcohol, and stained 
blue with 1 % ammonia water. Finally stained tissues were 
analyzed by light microscopy. Negative controls were 
incubated with PBS instead of primary antibodies.
Western blot analysis
Proteins were isolated from tumor specimens and nor-
mal lung tissues and the expression levels were meas-
ured using Western blot analysis. Briefly, 100 mg of the 
tumor specimens or normal lung tissues were minced on 
ice, washed 2 times with the cold PBS, and homogenized 
20–40 times in 1 mL mixture of radio-immunoprecipita-
tion assay (RIPA) buffer with protease inhibitor (Apply-
gen Technologies Inc, Beijing, China). After an ice bath 
for 10  min, homogenized samples were centrifuged at 
1000 rpm for another 10 min, and the supernatants were 
collected. Protein concentration was calculated using 
standard bovine serum albumin (BSA) curve. Approxi-
mately 30 μg of total proteins were separated by sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis and 
electrophoretically transferred to nitrocellulose mem-
branes. The membranes were blocked with 5  % milk in 
Tris-buffered saline (TBS) for 2 h at room temperature, 
followed by incubation with anti-Cox-2 (1:1000 dilu-
tion), anti- mPGES-1 (1:500 dilution), anti-E-Cadherin 
(1:1000 dilution), anti-N-Cadherin (1:1000 dilution), 
anti-Vimentin (1:1000 dilution), anti-VEGF (1:500), anti-
PDGFRβ (1:1000), anti-MMP-2 (1:300), anti-MMP-9 
(1:1000), anti-β-actin (1:1000), or anti-GAPDH (1:1000) 
antibodies. The membranes were incubated on a shaker 
overnight at 4  °C and then washed three times before 
incubating with the HRP-conjugated secondary antibod-
ies at a dilution of 1:2000 for 1  h at room temperature. 
The bands were visualized by adding ECL detection rea-
gent (Amersham Life Science, Piscataway, NJ, USA). 
The membranes were exposed to X-ray film and photo-
graphed by BIO-RAD ChemiDocXRS gel imaging sys-
tem. The pictures were exported by using Quantity One 
software. The intensities of the protein bands for target 
protein were quantified relative to β-actin or GAPDH 
bands from the same sample using image analysis soft-
ware ImageProPlus 4.5 (Diagnostic Instruments,USA).
Statistical analysis
All data are presented as mean  ±  standard devia-
tion (SD), while categorical variables are expressed as 
observed frequencies. One-way repeated-measures 
analysis of variance (ANOVA) and multiple comparisons 
tests were applied with Prism 6.0. All statistical tests were 
two-sided test, and p-values <0.05 were considered to be 
statistically significant.
Results
FLP ointment treatment exerted the best tumor growth 
inhibition rate at day 21 in Lewis lung cancer xenograft 
mice, and FLP in combination with celecoxib enhanced 
the antitumor effects.
Lewis lung cancer xenograft mice were used to evalu-
ate the tumor growth inhibition effects of FLP, celecoxib, 
and FLP in combination with celecoxib. At five time 
points (day 0, day 7, day 14, day 21, and day 28) we per-
formed in  vivo bioluminescence imaging and collected 
tumor from mice sacrificed by cervical dislocation at 3 
time points (day 14, day 21, and, day 28). The number 
of photons from mouse body surface area (Fig.  1a–c) 
and the tumor weight (Fig. 1d, e) were compared among 
each treatment group. In vivo bioluminescence imaging 
experiments showed that FLP ointment treatment signif-
icantly reduced the number of photons from the mouse 
body surface area (p  <  0.001). Moreover, FLP ointment 
treatment significantly reduced tumor weight at day 21 
compared with the control group (p < 0.01) and exhibited 
the highest tumor growth inhibition rate (37.3 %). These 
findings were consistent with in  vivo imaging results. 
Specially, FLP ointment in combination with celecoxib 
was more effective in reducing per/s/cm2/sr and increas-
ing the tumor growth inhibition rate compared with the 
FLP ointment alone, or celecoxib alone.
FLP ointment significantly inhibited the expression of 
Cox-2 in the tumor specimens at day 14, while in com-
bination with celecoxib did not exert obvious advan-
tages in inhibiting Cox-2 expression. Cox-2 is one of 
the key factors in maintaining the tumor inflammatory 
microenvironment. Cox-2 over-expression was found in 
lung cancer and was closely related to the prognosis of 
lung cancer patients [23]. We measured Cox-2 expres-
sion from the tumor specimens and normal lung tissue 
by immunohistochemistry and Western blot analysis at 
day 14, day 21, and day 28. The results showed that there 
was no obvious change in Cox-2 expression in the con-
trol group over time. However, FLP, celecoxib, or FLP in 
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combination with celecoxib treatment inhibited Cox-2 
expression compared with the control group at day 14 
(Fig. 2). Interestingly, there was no significant difference 
in Cox-2 expression between celecoxib alone and FLP in 
combination with celecoxib at day 14, whereas only FLP 
in combination with celecoxib treatment significantly 
inhibited Cox-2 expression (p < 0.01) at day 21 compared 
with the control group. On day 28, there was no signifi-
cant difference in Cox-2 expression between treatment 
groups and the control group.
Large number of inflammatory cell infiltrations were 
observed in the alveolar septum of Lewis lung cancer mice 
before and after metastasis
At day 28, we sacrificed mice and collected lung tissues 
to observe the rate of lung metastasis. The lung metas-
tasis rate was 80, 50, 60, and 30  % and the total num-
bers of metastatic nodules were 52, 20, 29, and 8 in the 
control group, FLP group, celecoxib group, and FLP 
with celecoxib group, respectively. In order to examine 
the inflammatory changes in lung tissues, we observed 
Fig. 1 Effects of FLP ointment on tumor growth in Lewis lung carcinoma xenograft mice. 5 × 105 LL/2-luc-M38 cells were implanted subcutane-
ously in C57BL/6 mouse. a Dynamic change of tumor growth measured by vivo bioluminescent signal; b The magnitude of tumor growth in vivo 
bioluminescent signal (p/s/cm2/s) at day 0, day 7, and day 14. c The magnitude of tumor growth in vivo bioluminescent signal (p/s/cm2/s) at day 
21 and day 28. d Tumor weight of the sacrificed mice at day 14, day 21, and day 28. e Tumor inhibition rate was calculated by (1 − average weight 
of tumors in treatment group/average weight of tumors in control group) × 100 %. Values were expressed as mean ± SD. **p < 0.01, *p < 0.05, 
***p < 0.001, and ****p < 0.0001. FLP Fei-Liu-Ping ointment group, C celecoxib group, FLP + C Fei-Liu-Ping ointment plus celecoxib group. FLP oint-
ment inhibited the tumor growth, while in combination with celecoxib exerted more significant anti-tumor growth effect at day 21 and day 28, and 
these findings were consistent with in vivo imaging results
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the changes of lung tissues before and after metastasis 
in the control group. The histological images indicated 
that a large number of inflammatory cell infiltrations 
were observed in the alveolar septum before the metas-
tasis formation (Fig. 3a-day 14), and after the formation 
of metastases (Fig.  3a-day 21). With the progression of 
tumor metastases, large numbers of new inflammatory 
cell infiltrations in the alveolar septum of the location 
around the metastases were found (Fig. 3a-day 28). This 
has raised questions as follows: does the Cox-2 expres-
sion change along with the time sequence in the lung 
metastatic microenvironment? Can anti-tumor metas-
tasis effect of FLP ointment, celecoxib, or FLP ointment 
in combination with celecoxib regulate tumor metasta-
sis inflammatory microenvironment by inhibiting Cox-2 
expression? To better understand these questions, we 
conducted the following experiments.
FLP ointment in combination with celecoxib synergistically 
inhibited Cox‑2 expression in the tumor metastasis 
microenvironment in a time‑dependent manner
Cox-2 expression is known to contribute to tumor metas-
tasis. We measured Cox-2 protein in the lung tissues by 
immunohistochemistry and Western blot analysis at day 
14, day 21, and day 28. The results showed that Cox-2 
expression was increased in a time-dependent manner 
Fig. 2 Effects of FLP ointment on Cox-2 expression in the tumor specimens. a Immunohistochemical analysis of Cox-2 expression (×200 magnifica-
tion and ×100 magnification). The brown or brown yellow represented positive Cox-2 protein. b A representative band of Cox-2 protein expression 
by Western blot analysis. c Relative protein level of Cox-2 (n = 3). Values were expressed as mean ± SD. **p < 0.01, *p < 0.05, ***p < 0.001, and 
****p < 0.0001. FLP Fei-Liu-Ping ointment group, C celecoxib group, FLP + C Fei-Liu-Ping ointment plus celecoxib group. FLP ointment significantly 
inhibited the Cox-2 expression in tumor specimens at the initial stage without exerting time-dependent inhibitory effect. FLP ointment in combina-
tion with celecoxib did not show obvious advantage in inhibiting Cox-2 expression
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in the control group. FLP ointment markedly inhibited 
Cox-2 expression at day 21 compared with the control 
group (p < 0.05), and the inhibitory effect was increased 
at day 28 (p  <  0.01). Celecoxib significantly inhibited 
Cox-2 expression at day 21 and day 28 (p  <  0.01). FLP 
ointment in combination with celecoxib significantly 
inhibited Cox-2 expression over time, and the inhibitory 
effect was increased in a time-dependent manner (Fig. 4). 
In addition, inflammatory cell infiltration was attenu-
ated to some extent in the treatment group. Since FLP 
ointment alone or FLP ointment in combination with 
celecoxib inhibited Cox-2 expression in a time-depend-
ent manner, we determined that the strongest inhibition 
occurred at day 28. We further investigated the changes 
of its downstream targets and metastasis related mPGES-
1, epithelial to mesenchymal transition (EMT), ECM, and 
angiogenesis-related protein expression.
FLP ointment in combination with celecoxib 
reduced mPGES‑1 expression in the lung metastasis 
microenvironment
Prostaglandin E2 (PGE2) can promote angiogenesis 
and tumor metastasis, attenuate cell apoptosis, and 
inhibit tumor immunity in various tumors [33]. PGE2 
is derived from the enzymatic release of arachidonic 
acid, which is metabolized by Cox and specific PGE 
syntheses. The mPGES-1, a subtype of PGE synthe-
ses, is an inducible enzyme that functions downstream 
Fig. 3 Effects of FLP ointment on histological changes and mPGES-1 expression in the lung tissues. a Histological analysis of the lung tissues in 
Lewis lung carcinoma xenograft mice. Large number of inflammatory cell infiltration was found in the alveolar septum around the metastasis loca-
tion in the control group, while inflammatory cell infiltration was alleviated in the treatment group. b Immunohistochemical analysis of mPGES-1 
expression in lung tissues (×200 magnification and ×100 magnification). The brown or brown yellow represented positive mPGES-1 protein. c A 
representative band of mPGES-1 protein expression by Western blot analysis. d Relative protein level of mPGES-1 (n = 3). Values were expressed as 
mean ± SD. **p < 0.01, *p < 0.05, ***p < 0.001, and ****p < 0.0001. FLP Fei-Liu-Ping ointment group, C celecoxib group, FLP + C Fei-Liu-Ping oint-
ment plus celecoxib group. FLP ointment in combination with celecoxib exerted a synergistic effect in inhibiting mPGES-1 expression
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of Cox- 2 in the PGE2 -biosynthesis pathway and often 
over-expressed in non-small cell lung cancer [34]. Over-
expression of mPGES-1 contributes to tumor growth, 
invasion, and metastasis [35]. As shown in Fig.  3b, 
mPGES-1 over-expression was identified in lung tissues 
of Lewis lung cancer mice. FLP ointment in combination 
with celecoxib was more effective than FLP ointment 
or celecoxib alone in inhibiting mPGES-1 expression. 
Immunohistochemistry image indicated that FLP oint-
ment more effectively inhibited mPGES-1 expression 
than celecoxib alone, while Western blot results showed 
that there was no statistically significant difference in 
mPGES-1 protein expression between the treatment and 
control groups (p > 0.05).
FLP ointment in combination with celecoxib inhibited 
VEGF and PDGFRβ expression
Angiogenesis is integral for tumor development, pro-
viding nutrients necessary for cell growth. Angiogen-
esis is required for the initiation of metastasis and plays 
an important role during initiation and end process of 
tumor metastasis. VEGF is the strongest angiogenesis 
stimulating factor [36]. PDGFRβ expression in endothe-
lial cells regulates VEGF transcription and secretion. The 
Fig. 4 Effects of FLP ointment on Cox-2 expression in the lung tissues. a Immunohistochemical analysis of Cox-2 expression (×200 magnifica-
tion and ×100 magnification). The brown or brown yellow represented positive Cox-2 protein. b A representative band of Cox-2 protein expression 
by Western blot analysis. c Relative protein level of Cox-2 (n = 3). Values were expressed as mean ± SD. **p < 0.01, *p < 0.05, ***p < 0.001, and 
****p < 0.0001. FLP Fei-Liu-Ping ointment group, C celecoxib group, FLP + C Fei-Liu-Ping ointment plus celecoxib group. FLP ointment in combina-
tion with celecoxib synergistically inhibited Cox-2 protein expression in the lung metastatic inflammatory microenvironment
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PDGF/PDGF receptor pathway is located on pericytes of 
the tumor stroma, and plays a pivotal role in angiogenesis 
and vessel maturation [37, 38]. As shown in Fig.  5, FLP 
ointment significantly inhibited VEGF protein expression 
(p  <  0.05). FLP ointment in combination with celecoxib 
exhibited the strongest inhibitory effect on VEGF protein 
expression (p < 0.001). Furthermore, FLP ointment com-
bined with celecoxib significantly inhibited PDGFRβ pro-
tein expression (p < 0.01).
FLP ointment in combination with celecoxib regulated 
EMT‑related proteins expression in the lung tissues 
of Lewis lung cancer mice
EMT is known to be involved in the invasion and metas-
tasis of malignant tumor cells [39]. EMT is defined 
as switching of polarized epithelial cells to a migra-
tory fibroblastoid phenotype. EMT refers the mor-
phology from epithelial to mesenchymal transition 
and achieves the migratory capacity, which might be a 
bridge between inflammation and tumor [40, 41]. The 
characteristics of EMT include the loss of EMT-related 
proteins expression, such as E-cadherin and keratin, and 
the up-regulation of interstitial related proteins expres-
sion, including N-cadherin, Vimentin, and Fibronectin. 
We measured E-cadherin, N-cadherin, and Vimentin 
expression in the lung tissue of Lewis lung cancer mice 
by immunohistochemistry and Western blot analysis. 
As shown in Fig. 6, E-cadherin expression was reduced, 
and N-cadherin and Vimentin expression was enhanced 
in the control group. FLP ointment increased E-cadherin 
expression, but significantly reduced N-cadherin and 
Vimentin expression.
FLP ointment in combination with celecoxib effectively 
reduced ECM‑related proteins expression
ECM is an important tissue barrier for tumor metasta-
sis. Deregulation of the ECM and basement membrane 
is the basic prerequisite for the cancer cell invasion 
and angiogenesis [34, 42]. One of the critical factors 
for tumor invasion is a large production of MMPs that 
principally participates in the degradation of basement 
membranes and ECM [43]. Type-IV collagen is a major 
Fig. 5 Effects of FLP ointment on VEGF and PDGFRβ expression in the lung tissues. a Immunohistochemical analysis of VEGF and PDGFRβ expres-
sion (×200 magnification and ×100 magnification). The brown or brown yellow represented positive VEGF and PDGFRβ protein. b A representative 
band of VEGF and PDGFRβ protein expression by Western blot analysis. c Relative protein level of VEGF and PDGFRβ (n = 3). Values were expressed 
as mean ± SD. **p < 0.01, *p < 0.05, ***p < 0.001, and ****p < 0.0001. FLP Fei-Liu-Ping ointment group, C celecoxib group, FLP + C Fei-Liu-Ping 
ointment plus celecoxib group. FLP ointment in combination with celecoxib inhibited VEGF and PDGFRβ protein expression in the lung metastatic 
inflammatory microenvironment
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constituent of the basement membrane. The major 
MMPs involved in tumor angiogenesis are MMP-2 and 
MMP-9 [44]. MMP-2 and MMP-9 play critical roles 
in the degradation of type-IV collagen [45]. Moreover, 
MMP-9 mainly regulates the bioavailability of VEGF, 
the most potent inducer of tumor angiogenesis [46]. 
As shown in Fig. 7, FLP ointment inhibited the MMP-2 
expression and MMP-9 (p  <  0.001). FLP ointment 
in combination with celecoxib further inhibited the 
expression of MMP2 and MMP9.
Discussion
This study investigated the effect of FLP on the regula-
tion of tumor metastatic inflammatory microenviron-
ment. FLP ointment inhibited Cox-2 expression of the 
tumor specimens. More importantly, it also inhibited 
Cox-2 expression of the normal lung tissues in the tumor 
metastatic inflammatory microenvironment in a time-
dependent manner. Our study demonstrated for the first 
time that FLP ointment in combination with celecoxib 
adjunctly regulates Cox-2 mediated metastasis-related 
Fig. 6 Effects of FLP ointment on E-cadherin, N-cadherin, and Vimentin expression in the lung tissues. a Immunohistochemical analysis of 
E-cadherin, N-cadherin, and Vimentin expression (×200 magnification and ×100 magnification). The brown or brown yellow represented positive 
E-cadherin, N-cadherin, and Vimentin protein. b A representative band of E-cadherin, N-cadherin, and Vimentin protein expression by Western 
blot analysis. c Relative protein level of E-cadherin, N-cadherin, and Vimentin (n = 3). Values were expressed as mean ± SD. **p < 0.01, *p < 0.05, 
***p < 0.001, and ****p < 0.0001. FLP Fei-Liu-Ping ointment group, C celecoxib group, FLP + C Fei-Liu-Ping ointment plus celecoxib group. FLP 
ointment in combination with celecoxib synergistically inhibited EMT-related E-cadherin, N-cadherin, and Vimentin protein expression in the lung 
metastatic inflammatory microenvironment
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proteins expression in the microenvironment. Thus, inte-
grated therapy provided better efficacy in the prevention 
of lung metastasis in the Lewis lung carcinoma xenograft 
mouse model.
FLP ointment has been used to treat lung cancer and 
has been suggested to prevent lung cancer metastasis or 
recurrence for many years in China [47]. FLP ointment 
has been developed based on the Differentiation of Syn-
drome of TCM theory for lung cancer or lung metasta-
sis patients with deficiency of both Qi and Yin. FLP has 
potential to improve the quality of life, inhibit tumor 
growth, and prolong survival of lung cancer patients. 
Our previous study [31] showed that FLP promotes den-
dritic cell maturation and regulates tumor inflammatory 
microenvironment in  vitro, and inhibits tumor growth 
and invasion through regulating NF- kappa B pathway 
in tumors of the Lewis lung carcinoma xenograft mouse 
model in vivo. Moreover, FLP also reduces serum TNF-
α, IL-1β, and IL-6 level in a Lewis lung carcinoma xeno-
graft mouse. The potential mechanism of action of FLP 
ointment on the lung cancer treatment and prevention 
is presented in Fig.  8. The current study indicated that 
the tumor inhibition rate was 37.3 % at day 21, and this 
finding was consistent with the absolute number of pho-
tons from mouse body surface area that was seen from 
in  vivo bioluminescence imaging at day 21. However, 
these results could not demonstrate the anti-tumor 
effect of FLP via inhibition of Cox-2 expression since 
FLP ointment only effectively inhibited Cox-2 expres-
sion at day 14. In addition, vivo bioluminescence imaging 
experiment might replace regularly sacrificed mice in the 
observation of the tumor changes.
Reducing tumor-associated inflammation and pre-
venting recurrence and metastasis are crucial therapeu-
tic strategies for the management of cancer patients. 
Chinese medicine practitioners believe that the biggest 
advantage of TCM is not only the inhibition of tumor 
growth, but also the prevention of tumor recurrence and 
metastasis. According to the basic theory of TCM, the 
concept of holism in TCM is consistent with the tumor 
Fig. 7 Effects of FLP ointment on MMP-9 and MMP-2 expression in the lung tissues. a Immunohistochemical analysis of MMP-9 and MMP-2 
expression (×200 magnification and ×100 magnification). The brown or brown yellow represented positive Cox-2 protein. b A representative band 
of MMP-9 and MMP-2 protein expression by Western blot analysis. c Relative protein level of MMP-9 and MMP-2 (n = 3). Values were expressed as 
mean ± SD. **p < 0.01, *p < 0.05, ***p < 0.001, and ****p < 0.0001. FLP Fei-Liu-Ping ointment group, C celecoxib group, FLP + C Fei-Liu-Ping oint-
ment plus celecoxib group. FLP ointment in combination with celecoxib synergistically inhibited ECM-related MMP-9 and MMP-2 protein expres-
sion in the lung metastatic inflammatory microenvironment
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microenvironment just as macroscopical and micro-
scopical aspects. Therefore, we hypothesized that the 
mechanism of TCM in preventing tumor recurrence and 
metastasis rely on regulation of the tumor microenviron-
ment [31]. The crucial event in the course of lung can-
cer is its metastatic spread to distant organs. Metastatic 
cancer cells (‘seeds’) arise from the primary tumors need 
to create a specific organ microenvironments (‘soil’), 
which is called organ targeting [48].The tumor micro-
environment can be divided into three categories: core 
of primary tumor microenvironment, invasive tumor 
microenvironment, and metastatic tumor microenviron-
ment [5]. We hypothesized that TCM therapies might 
prevent the affinity of “seed and soil” through regulating 
the tumor metastatic microenvironment and preventing 
tumor recurrence and metastasis. The current study also 
demonstrated increased Cox-2 expression in the lung 
metastatic microenvironment and that the inhibitory 
effect of FLP ointment on Cox-2 expression was strength-
ened over time. This suggested that TCM therapies 
reduce the risk of lung metastasis through effective regu-
lation of the metastatic inflammatory microenvironment.
Previous studies have suggested that celecoxib inhib-
its Cox-2 expression in a variety of tumors, such as 
colon cancer, lung cancer, breast cancer, gastric cancer, 
and prostate cancer, and plays role in regulating tumor 
occurrence and progression [49–53]. However, the appli-
cation of Cox-2 inhibitor for the treatment and preven-
tion of cancer remains controversial. Anti-tumor effects 
of Cox-2 inhibitor alone or in combination with other 
chemotherapy drugs have been widely investigated, and 
many trials have shown inspiring results. For example, a 
Phase II study showed that treatment of celecoxib with 
cisplatin plus etoposide in extensive-stage small cell lung 
cancer was safe and feasible [54]. A phase I and pharma-
cokinetic studies demonstrated an antitumor effect of 
celecoxib in combination with ocetaxel and irinotecan 
[55]. The combination of the celecoxib and paclitaxel has 
been considered as the second-line therapy for non-small 
cell lung cancer [56]. On the contrary, chemotherapy or 
Fig. 8 Potential mechanisms of FLP ointment on the lung cancer treatment and prevention. a FLP ointment can inhibit the proliferation of A549 
cells. b Possible inflammatory network signal pathways of FLP ointment. c Previous and the current experiment demonstrated that FLP ointment 
inhibited metastasis through the regulation of tumor inflammatory microenvironment. d–f Previous and the current experiment showed that 
FLP ointment inhibited angiogenesis, prevented extracellular matrix remodeling, and regulated epithelial-mesenchymal transition. g Clinical trials 
confirmed the efficacy of FLP ointment
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targeted drugs in combination with celecoxib did not 
improve the patient survival or remission rate in two 
clinical trials [57, 58]. Celecoxib inhibited tumor growth 
and lung metastasis in Lewis lung carcinoma xenograft 
C57BL/6 mice, and the mechanism was related to the 
early inhibition of the Cox-2 expression of the tumor 
specimens [49]. In our study, FLP ointment in combi-
nation with celecoxib exerted significant advantages 
in inhibiting Cox-2 expression in the lung metastatic 
microenvironment. The synergistic effect might be partly 
explained by the celecoxib-mediated stable and continu-
ous inhibition of Cox-2 expression in lung metastatic 
microenvironment and FLP ointment- mediated inhibi-
tion of Cox-2 expression in a time-dependent manner 
(Fig.  4). FLP ointment inhibited Cox-2 and metastasis- 
related downstream proteins. FLP ointment was superior 
to celecoxib in inhibiting MMP-9 and Vimentin protein 
expression. FLP might regulate these pathways via sec-
ondary inhibition of upstream pathways, or by directly 
inhibiting target protein expression. At the same, FLP 
ointment in combination with celecoxib synergistically 
inhibited angiogenesis and EMT or ECM- related protein 
expression.
To the best of our knowledge, no previous literature 
has reported the combined use of TCM and celecoxib 
in the treatment and prevention of cancer. Our find-
ings could provide some basis for future clinical trials. 
Further studies are warranted to elucidate whether FLP 
ointment in combination with celecoxib can clinically 
provide the best efficacy in the prevention of recurrence 
and metastasis.
Conclusions
This study demonstrated that FLP ointment is effective 
in regulating the metastatic inflammatory microenviron-
ment from multi-target via inhibition of Cox-2 expression 
and regulating lung metastasis-related proteins. Treat-
ment of FLP ointment in combination with celecoxib 
adjunctly inhibits tumor growth and lung metastasis in 
a Lewis lung carcinoma xenograft mouse model. TCM 
combined with anti-inflammatory drugs might be a 
promising strategy in the prevention of tumor metastasis. 
Moreover, TCM might be a potential candidate drug of 
maintenance therapy. Further studies on anti-tumor and 
anti-metastatic effect of TCM may significantly contrib-
ute to the management of lung cancer patients.
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